Nirmesh Patel describes his path from biomedical research at King’s College and a PhD focused on triple-negative breast cancer to founding CCG AI. He founded the company while finishing his PhD and credits Y Combinator with helping him build a valuable network. After CCG AI was sold, Nirmesh moved from advising startups into venture investing, eventually helping establish Amino Collective. The firm invests early in companies at the intersection of AI, technology, health, and biology, backing ambitious founders across areas such as clinical infrastructure, agentic workflows, and drug discovery.
Nirmesh says he looks for founders who are deeply driven by the problem, move with urgency, and can make a seemingly unconventional opportunity feel inevitable. He also shares practical guidance: prepare carefully for board meetings, use data to inform pivots, ask critical go/no-go questions early, and treat investor feedback as input rather than instruction. He emphasizes that failure is not inherently a black mark; delaying hard decisions or avoiding honesty about them can be more damaging.
Time Stamps
00:00:16 — Upbringing and academic path into biomedical research
00:04:28 — Founding a company during his PhD and balancing it with thesis work
00:11:37 — Transition from founder to investor
00:16:13 — Amino Collective’s investment thesis and “free and radical” founders
00:28:10 — Biotech funding conditions and the outlook for early-stage investment
00:34:10 — Overlooked opportunities in drug discovery, capital allocation, and chemistry
00:37:44 — Founder qualities Patel looks for and advice on pitching
00:42:30 — Making pivots based on evidence and gathering the right data
00:47:37 — Startup setbacks and learning from failure
00:54:13 — Quickfire round and conclusions